An Irish MedTech company has announced a major European expansion which will see its treatment device being made available to more than 7 million tinnitus sufferers in the UK.
Neuromod Devices Lts, which is based in Dublin, says it is in partnership with The Tinnitus Clinic and is launching a telemedicine service in UK – with the Lenire tinnitus treatment device also being launched in Switzerland.
Neuromod specialises in non-invasive neuromodulation technologies and has developed Lenire, the first non-invasive bimodal neuromodulation tinnitus device, clinically proven in large-scale clinical trials to soothe and relieve tinnitus.
Tinnitus affects between 10 and 15% of the global population. The company estimates that approximately eight million people across the two countries suffer from tinnitus, a condition commonly known as ‘ringing in the ears’.
Speaking on this news, Dr Ross O’Neill, CEO of Neuromod Devices said: “I am absolutely delighted to announce our entry into two really important markets: the UK and Switzerland. As the company has scaled up over the past 12 months, as well as our operations in Ireland, Germany, Austria and Belgium, we’ve been focusing on the logistical challenges of making Lenire available to patients in as many European countries as possible. We had been treating a small number of UK-resident patients via our telemedicine service, so it’s good to be able to expand the provision of our services and the Lenire device in these countries”.
The Lenire tinnitus treatment device is available to people with tinnitus through The Tinnitus Clinic’s network of seven locations across the UK or online via the company’s Neuromod Medical tinnitus telemedicine service.
The Tinnitus Clinic’s audiologists will provide Lenire to patients, as well as devising and monitoring their tinnitus treatment plans using the device. The Tinnitus Clinic is the leading provider of the latest evidence-based tinnitus treatments in the UK, with clinics in London, Bristol, Leeds, Leicester, Manchester, Newcastle, and Stirling (Scotland).
Patients in the United Kingdom can also opt to have tinnitus assessments online via the company’s telemedicine service, launched earlier this year in Ireland, which has proved to be popular. The service is delivered through Neuromod Medical, a centre of excellence for tinnitus care, based at the Hermitage Medical Clinic in Dublin and aims to provide patients with quick access to tinnitus care, without waiting lists.
With this service patients can get assessed, fitted for the Lenire device and complete follow up appointments with their healthcare professional via video call from the comfort of their own homes, using a mobile device or home computer.
Lenire has also launched in Switzerland, where the device is available to tinnitus patients from 10 clinical partners throughout the country, in places such as Geneva, Bern and Basel. A full list of European partners can be viewed at the Lenire website.
Dr O’Neill continued: “Finding an effective and long-lasting treatment for tinnitus has been a source of stress for tinnitus patients around the world for a long time. Recently, with tinnitus being a common symptom of long COVID, the demand for an effective tinnitus therapy has increased. At Neuromod, our goal with Lenire is to improve the quality of life of those suffering from tinnitus and this is what motivates us to bring this treatment to as many people as we can. The results of large-scale clinical trials, involving more than 500 participants, are very positive, as are the real-world outcomes for our patients in Ireland and Germany so this is a very exciting time for the company”.
Neuromod has been advancing the commercialisation of Lenire across Europe having opened its German office in Forchheim, Bavaria last year. Since then, the company has made Lenire available to patients in Germany by taking on 57 partners who make the device and its treatment plan available in 96 clinics throughout Germany. Neuromod also has three partner clinics in Austria.
The company, which raised €10.5 million in an oversubscribed Series B financing round late last year, has been scaling manufacturing of the Lenire device to meet demand in Europe. This funding has also seen the employee numbers at the company grow by more than 50% in six months. which is being used to expand European commercialisation and scale-up manufacturing of the Lenire device to meet demand.
Lenire is prescribed and fitted under the supervision of a qualified healthcare professional who specialises in the field of tinnitus treatment such as audiologists and Consultant Otolaryngologists or ENT (Ear, Nose and Throat) surgeons.
The device has been used in large-scale clinical trials, the most recent of which, involving 326 participants, delivered dramatic improvements in patients’ tinnitus symptoms. 86.2% of treatment-compliant participant reported an improvement in their tinnitus symptoms after a 12-week treatment period. When followed up 12 months post treatment, 80.1% of these participants had sustained the improvements. This study represents one of the largest and longest followed-up clinical trial ever conducted in the tinnitus field, the company said.